The role of CB1 in intestinal permeability and inflammation

FASEB Journal

Volumn 31, Issue 8, 2017, Pages 3267-3277

  Karwad, Mustafa A ^d   Couch, Daniel G ^d   Theophilidou, Elena ^d   Sarmad, Sarir ^a   Barrett, David A ^a   Larvin, Michael ^b   Wright, Karen L ^c   Lund, Jonathan N ^d   O’Sullivan, Saoirse E ^d  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF LIMERICK   (Ireland)

^c LANCASTER UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

2 ag; Anandamide; Endocannabinoids; Gut

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2 CHLORO 5 NITROBENZANILIDE; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; OXYGEN; TUMOR NECROSIS FACTOR; 1,3 BENZODIOXOLE DERIVATIVE; ACYLGLYCEROL; ACYLGLYCEROL LIPASE; AMIDASE; AMIDE; ARACHIDONIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; CYTOKINE; FATTY-ACID AMIDE HYDROLASE; GLYCERYL 2-ARACHIDONATE; PIPERIDINE DERIVATIVE;

APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CACO-2 CELL LINE; COLON TISSUE; COLORECTAL SURGERY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; INFLAMMATION; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; INTESTINE ISCHEMIA; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; PRIORITY JOURNAL; TRANSEPITHELIAL RESISTANCE; WILD TYPE; ANTAGONISTS AND INHIBITORS; COLORECTAL TUMOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMPEDANCE; INTESTINE; METABOLISM; OXYGEN CONSUMPTION; PATHOLOGY; PERMEABILITY; PHYSIOLOGY; TISSUE CULTURE TECHNIQUE;

AMIDOHYDROLASES; ARACHIDONIC ACIDS; BENZAMIDES; BENZODIOXOLES; CACO-2 CELLS; CARBAMATES; COLORECTAL NEOPLASMS; CYTOKINES; ELECTRIC IMPEDANCE; ENDOCANNABINOIDS; GENE EXPRESSION REGULATION; GLYCERIDES; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; INTESTINES; MONOACYLGLYCEROL LIPASES; OXYGEN CONSUMPTION; PERMEABILITY; PIPERIDINES; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; TISSUE CULTURE TECHNIQUES;

EID: 85026818617     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201601346R     Document Type: Article

References (46)

1. Groschwitz, K. R. and and Hogan, S. P. (2009) Intestinal barrier function: molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 124, 3–20
2. Van der Flier, L. G., and Clevers, H. (2009) Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu. Rev. Physiol. 71, 241–260
3. Kim, Y. S., and Ho, S. B. (2010) Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr. Gastroenterol. Rep. 12, 319–330
4. Coskun, M. (2014) Intestinal epithelium in inflammatory bowel disease. Front Med (Lausanne) 1, 24
5. Peterson, L. W., and Artis, D. (2014) Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14, 141–153
6. Elkouby-Naor, L., and Ben-Yosef, T. (2010) Functions of claudin tight junction proteins and their complex interactions in various physiological systems. Int. Rev. Cell Mol. Biol. 279, 1–32
7. Shen, L. (2012) Tight junctions on the move: molecular mechanisms for epithelial barrier regulation. Ann. N. Y. Acad. Sci. 1258, 9–18
8. Fasano, A., and Nataro, J. P. (2004) Intestinal epithelial tight junctions as targets for enteric bacteria-derived toxins. Adv. Drug Deliv. Rev. 56, 795–807
9. Sonoda, N., Furuse, M., Sasaki, H., Yonemura, S., Katahira, J., Horiguchi, Y., and Tsukita, S. (1999) Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J. Cell Biol. 147, 195–204
10. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949
11. Muccioli, G. G. (2010) Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov. Today 15, 474–483
12. Freund, T. F., Katona, I., and Piomelli, D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 1017–1066
13. Di Marzo, V., and Piscitelli, F. (2015) The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics 12, 692–698
14. Blankman, J. L., Simon, G. M., and Cravatt, B. F. (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14, 1347–1356
15. Lee, Y., Jo, J., Chung, H. Y., Pothoulakis, C., and Im, E. (2016) Endocannabinoids in the gut. Am. J. Physiol. Gastrointest. Liver Physiol. 4, G655–G666
16. Alhamoruni, A., Lee, A. C., Wright, K. L., Larvin, M., and O’Sullivan, S. E. (2010) Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J. Pharmacol. Exp. Ther. 335, 92–102
17. Alhamoruni, A., Wright, K. L., Larvin, M., and O’Sullivan, S. E. (2012) Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br. J. Pharmacol. 165, 2598–2610
18. Di Sabatino, A., Battista, N., Biancheri, P., Rapino, C., Rovedatti, L., Astarita, G., Vanoli, A., Dainese, E., Guerci, M., Piomelli, D., Pender, S. L., MacDonald, T. T., Maccarrone, M., and Corazza, G. R. (2011) The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol. 4, 574–583
19. Godlewski, G., Malinowska, B., and Schlicker, E. (2004) Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. Br. J. Pharmacol. 142, 701–708
20. Villanueva, A., Yilmaz, S. M., Millington, W. R., Cutrera, R. A., Stouffer, D. G., Parsons, L. H., Cheer, J. F., and Feleder, C. (2009) Central cannabinoid 1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area. Shock 32, 614–620
21. Caraceni, P., Pertosa, A. M., Giannone, F., Domenicali, M., Grattagliano, I., Principe, A., Mastroleo, C., Perrelli, M. G., Cutrin, J., Trevisani, F., Croci, T., and Bernardi, M. (2009) Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. Gut 58, 1135–1143
22. Matsuda, K., Mikami, Y., Takeda, K., Fukuyama, S., Egawa, S., Sunamura, M., Maruyama, I., and Matsuno, S. (2005) The cannabinoid 1 receptor antagonist, AM251, prolongs the survival of rats with severe acute pancreatitis. Tohoku J. Exp. Med. 207, 99–107
23. Engel, M. A., Kellermann, C. A., Rau, T., Burnat, G., Hahn, E. G., and Konturek, P. C. (2008) Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide. J. Physiol. Pharmacol. 59, 673–689
24. Troy-Fioramonti, S., Demizieux, L., Gresti, J., Muller, T., Vergès, B., and Degrace, P. (2015) Acute activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice. Diabetes 64, 808–818
25. Harvey, B. S., Nicotra, L. L., Vu, M., and Smid, S. D. (2013) Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine 63, 209–217
26. D’Argenio, G., Valenti, M., Scaglione, G., Cosenza, V., Sorrentini, I., and Di Marzo, V. (2006) Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 20, 568–570
27. Shamran, H., Singh, N. P., Zumbrun, E. E., Murphy, A., Taub, D. D., Mishra, M. K., Price, R. L., Chatterjee, S., Nagarkatti, M., Nagarkatti, P. S., and Singh, U. P. (2016) Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation. Brain Behav. Immun. 59, 10–20
28. Sałaga, M., Mokrowiecka, A., Zakrzewski, P. K., Cygankiewicz, A., Leishman, E., Sobczak, M., Zatorski, H., Małecka-Panas, E., Kordek, R., Storr, M., Krajewska, W. M., Bradshaw, H. B., and Fichna, J. (2014) Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). J. Crohn’s Colitis 8, 998–1009
29. Koay, L. C., Rigby, R. J., and Wright, K. L. (2014) Cannabinoid-induced autophagy regulates suppressor of cytokine signaling-3 in intestinal epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 307, G140–G148
30. Shore, D. M., Baillie, G. L., Hurst, D. H., Navas, F., Seltzman, H. H., Marcu, J. P., Abood, M. E., Ross, R. A., and Reggio, P. H. (2014) Allosteric Modulation of a Cannabinoid G Protein-coupled Receptor. J. Biol. Chem. 289, 5828–5845
31. Richardson, D., Ortori, C. A., Chapman, V., Kendall, D. A., and Barrett, D. A. (2007) Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal. Biochem. 360, 216–226
32. Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., and Piomelli, D. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9, 76–81
33. Piomelli, D., Tarzia, G., Duranti, A., Tontini, A., Mor, M., Compton, T. R., Dasse, O., Monaghan, E. P., Parrott, J. A., and Putman, D. (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 12, 21–38
34. Smart, D., Jonsson, K.-O., Vandevoorde, S., Lambert, D. M., and Fowler, C. J. (2002) ‘Entourage’ effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br. J. Pharmacol. 136, 452–458
35. Jonsson, K. O., Vandevoorde, S., Lambert, D. M., Tiger, G., and Fowler, C. J. (2001) Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br. J. Pharmacol. 133, 1263–1275
36. Ho, W.-S. V., Barrett, D. A., and Randall, M. D. (2008) ‘Entourage’ effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 155, 837–846
37. Sugiura, T., Kodaka, T., Kondo, S., Tonegawa, T., Nakane, S., Kishimoto, S., Yamashita, A., and Waku, K. (1996) 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. 229, 58–64
38. Sugiura, T., Kodaka, T., Kondo, S., Nakane, S., Kondo, H., Waku, K., Ishima, Y., Watanabe, K., and Yamamoto, I. (1997) Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells. J. Biochem. 122, 890–895
39. Sugiura, T., Kodaka, T., Nakane, S., Miyashita, T., Kondo, S., Suhara, Y., Takayama, H., Waku, K., Seki, C., Baba, N., and Ishima, Y. (1999) Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 274, 2794–2801
40. Di Marzo, V., and Izzo, A. A. (2006) Endocannabinoid overactivity and intestinal inflammation. Gut 55, 1373–1376
41. D’Argenio, G., Petrosino, S., Gianfrani, C., Valenti, M., Scaglione, G., Grandone, I., Nigam, S., Sorrentini, I., Mazzarella, G., and Di Marzo, V. (2007) Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J. Mol. Med. (Berl.) 85, 523–530
42. Guagnini, F., Valenti, M., Mukenge, S., Matias, I., Bianchetti, A., Di Palo, S., Ferla, G., Di Marzo, V., and Croci, T. (2006) Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut 55, 946–953
43. Pastor Rojo, O., López San Román, A., Albéniz Arbizu, E., de la Hera Martínez, A., Ripoll Sevillano, E., and Albillos Martínez, A. (2007) Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13, 269–277
44. Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B. F., Ferri, G.-L., Sibaev, A., Storr, M., and Lutz, B. (2004) The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113, 1202–1209
45. Harvey, B. S., Sia, T. C., Wattchow, D. A., and Smid, S. D. (2014) Interleukin17Aevokedmucosaldamageisattenuatedbycannabidiol and anandamide in a human colonic explant model. Cytokine 65, 236–244
46. Nicotra, L. L., Vu, M., Harvey, B. S., and Smid, S. D. (2013) Prostaglandin ethanolamides attenuate damage in a human explant colitis model. Prostaglandins Other Lipid Mediat. 100-101, 22–29